Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics at diagnosis stratified according to the median of the early DXR-BMD lossa

From: Early changes in bone mineral density measured by digital X-ray radiogrammetry predict up to 20 years radiological outcome in rheumatoid arthritis

  High bone loss Low bone loss  
  (higher than median) (less than median) Pvalue
Patient characteristics (n = 69) ( n = 66)  
Baseline characteristics    
   Mean age, yr (± SD) 57.7 (11.4) 46.4 (11.4) <0.001
   Mean symptom duration at inclusion, months (± SD) 10.6 (6.8) 13.0 (7.1) 0.035
   Mean HAQ, 0 to 3 (± SD) 1.0 (0.6) 0.7 (0.6) 0.004
   Mean DAS44, 0 to 10 (± SD) 3.5 (1.1) 3.0 (1.0) 0.024
   Mean CRP, mg/l (± SD) 34 (36) 18 (31) <0.001
   Mean ESR, mm/1 hour (± SD) 46 (30) 28 (25) <0.001
   Female, % 62% 67% ns
   RF-positive, % 81% 85% ns
   ACPA-positive, % 78% 74% ns
   Smoker, % 34% 32% ns
   Mean Larsen score, 0 to 200 (± SD) 10.2 (9.4) 6.6 (6.2) 0.100
   Mean BMD, g/cm2 (± SD) 0.57 (0.09) 0.62 (0.07) <0.001
   Early DXR-BMD loss, g/cm2 (± SD) -0.0418 (0.02) -0.0034 (0.008) <0.001
   Early DXR-BMD loss, % -7.6 -0.57 <0.001
Treatment during total observation period, %    
   DMARDs ever, % 80% 71% ns
   MTX ever, % 39% 42% ns
   Prednisolone ever, % 48% 47% ns
  1. aSD, standard deviation; DXR-BMD, bone mineral density (BMD) measured by digital X-ray radiogrammetry; HAQ, Health Assessment Questionnaire; DAS44, Disease Activity Score using 44 joint counts; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anticitrullinated peptide antibodies; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; ns, not significant. Medication refers to treatment for the whole observation period.